Telix Pharmaceuticals Limited

Telix Pharmaceuticals Limited is a global biopharmaceutical company headquartered in Melbourne, Australia, dedicated to developing innovative diagnostic and therapeutic radiopharmaceuticals. Their mission is to improve the lives of patients with serious diseases by providing them with access to cutting-edge nuclear medicine solutions.

Telix focuses on the development of targeted radiopharmaceuticals, which combine a radioactive atom with a targeting molecule that specifically binds to cancer cells or other disease-related targets. This allows for the delivery of radiation directly to the diseased tissue, minimizing damage to healthy cells and tissues.

The company's current pipeline includes several promising radiopharmaceuticals in various stages of development, targeting a range of cancers and other diseases. These include:

• Illuccix® (girentuximab): A diagnostic imaging agent for the detection of prostate-specific membrane antigen (PSMA) in men with suspected prostate cancer.
• TLX591 (lanreotide): A therapeutic radiopharmaceutical for the treatment of neuroendocrine tumors.
• TLX250-CDx (obinutuzumab): A diagnostic imaging agent for the detection of CD20-positive B-cell malignancies.

Telix is committed to advancing the field of nuclear medicine and improving patient outcomes. Their innovative radiopharmaceuticals offer the potential to significantly improve the diagnosis and treatment of serious diseases, providing patients with new hope and better quality of life.